In some solid tumors, mainly non-small-cell lung cancer (NSCLC), several retrospective studies clearly correlate the occurrence of irAEs under anti-PD1 with an improved response [14,15]; whereas in melanoma, this relationship is less clear [14,16,17,18]. The gene discussed is PDCD1; the disease is melanoma.